These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
192 related articles for article (PubMed ID: 26080282)
21. Common variable immunodeficiency, impaired neurological development and reduced numbers of T regulatory cells in a 10-year-old boy with a STAT1 gain-of-function mutation. Kobbe R; Kolster M; Fuchs S; Schulze-Sturm U; Jenderny J; Kochhan L; Staab J; Tolosa E; Grimbacher B; Meyer T Gene; 2016 Jul; 586(2):234-8. PubMed ID: 27063510 [TBL] [Abstract][Full Text] [Related]
22. Bronchiectasis and Recurrent Respiratory Infections with a Huh HJ; Jhun BW; Choi SR; Kim YJ; Yun SA; Nham E; Kong T; Ki CS; Koh WJ Yonsei Med J; 2018 Oct; 59(8):1004-1007. PubMed ID: 30187709 [TBL] [Abstract][Full Text] [Related]
23. STAT1 gain-of-function compromises skin host defense in the context of IFN-γ signaling. Niehues H; Rösler B; van der Krieken DA; van Vlijmen-Willems IMJJ; Rodijk-Olthuis D; Peppelman M; Schalkwijk J; van den Bogaard EHJ; Zeeuwen PLJM; van de Veerdonk FL J Allergy Clin Immunol; 2019 Apr; 143(4):1626-1629.e5. PubMed ID: 30576757 [No Abstract] [Full Text] [Related]
36. Heterozygous gain-of-function mutations in human STAT1: A case of hemophagocytic lymphohistiocytosis due to chronic mucocutaneous candidiasis in a 17-month-old male. Ruan P; Zhang Y; Chen H; Chen H; Dong Z Pediatr Blood Cancer; 2023 Jun; 70(6):e30284. PubMed ID: 36881481 [No Abstract] [Full Text] [Related]
37. Baricitinib treatment in a patient with a gain-of-function mutation in signal transducer and activator of transcription 1 (STAT1). Meesilpavikkai K; Dik WA; Schrijver B; Nagtzaam NMA; Posthumus-van Sluijs SJ; van Hagen PM; Dalm VASH J Allergy Clin Immunol; 2018 Jul; 142(1):328-330.e2. PubMed ID: 29729898 [No Abstract] [Full Text] [Related]
38. Utility of ruxolitinib in a patient with chronic mucocutaneous candidiasis caused by STAT1 gain-of-function mutation. Olivier N; Boralevi F; Fricain JC; Doutre MS J Eur Acad Dermatol Venereol; 2022 Nov; 36(11):e899-e902. PubMed ID: 35696308 [No Abstract] [Full Text] [Related]
39. The potential role for topical imiquimod in the treatment of chronic mucocutaneous candidiasis caused by gain-of-function mutation in STAT1: A case-report. Reis J; van de Veerdonk FL; Carvalho A; Fernandes A; Machado S Dermatol Ther; 2021 Sep; 34(5):e15043. PubMed ID: 34176198 [No Abstract] [Full Text] [Related]
40. STAT1 Gain-of-Function and Dominant Negative STAT3 Mutations Impair IL-17 and IL-22 Immunity Associated with CMC. Hiller J; Hagl B; Effner R; Puel A; Schaller M; Mascher B; Eyerich S; Eyerich K; Jansson AF; Ring J; Casanova JL; Renner ED; Traidl-Hoffmann C J Invest Dermatol; 2018 Mar; 138(3):711-714. PubMed ID: 29054602 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]